10 research outputs found
Treatment of Early Folliculotropic Mycosis Fungoides with Special Focus on Psoralen plus Ultraviolet A
Data on the treatment of early folliculotropic mycosis fungoides, a recently defined clinicopathological subgroup of folliculotropic mycosis fungoides with an indolent course, is limited. Treatment outcomes were studied in a retrospective cohort of 47 adults with early folliculotropic mycosis fungoides, with a focus on psoralen plus ultraviolet A (PUVA) monotherapy, including dosimetric data, and the findings were compared with data for PUVA in 18 adults with early-classic mycosis fungoides. PUVA was given to 27 patients with early folliculotropic mycosis fungoides: 70% achieved complete response and 26% partial response. Significantly more treatments were needed to achieve complete response in stage IB compared with stage IA. There was no significant difference in the complete response rate from classic plaque-stage disease, although the early folliculotropic mycosis fungoides group required more treatments to achieve complete response, and a higher cumulative dose of UVA. Thus, PUVA is an effective treatment for early folliculotropic mycosis fungoides. Its complete response rate might be equal to early-classic mycosis fungoides; however, a longer induction phase is needed to achieve complete response
Biologic treatment of recalcitrant pediatric psoriasis: a case series from a tertiary medical center
The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data
Literature regarding the effect of biologics on the course of mycosis
fungoides (MF) is scarce. This multi-centre study analysed retrospective
data on 19 patients with MF, who were treated with biologics; 12 for
inflammatory conditions coexisting with MF, and 7 for MF misdiagnosed as
an inflammatory skin disease. Eight patients were treated with
anti-tumour necrosis factor-alpha-monotherapy; 6 had early-stage MF, in
3 patients MF preceded and in 3 MF was diagnosed after initiation of
biologics, with no stage-progression or with stable disease,
respectively (median treatment time concurrent with MF 57 months). Two
patients had advanced stage MF: IIB, treated for 15 months with no
stage-progression, and IVA1, treated for 8 months, died of disease 10
months later. The other 11/19 patients received anti-interleukin-17A
and/or anti-interleukin-12/23 or anti-interleukin-23 (with/without
anti-tumour necrosis factor-alpha/anti-interleukin-4/13), with
stage-progression in 8 patients after a median of 8 months' treatment.
Although, in general, biologics should be avoided in patients with MF,
these results indicate that anti-tumour necrosis
factor-alpha-monotherapy might not aggravate the disease course in
early-stage patients. Interleukin-17A, interleukin-12/23 and
interleukin-23 pathway-blockers may prompt progression of MF